The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh ImpactUpdated•Originally published 25 March 2026•Updated 26 March 2026•

1 min read

FDA Approves Corcept Therapeutics' Lifyorli for Ovarian Cancer Treatment

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1The U.S. FDA approved Lifyorli (relacorilant) in combination with nab-paclitaxel.

2 months ago

Version History

1 additional source confirmed this story

Version 12 months ago

What changed: Updated the story to include the positive market reaction and share price jump, while highlighting the treatment's status as a first-of-its-kind therapy.

Corcept Therapeutics (NASDAQ: CORT) has received U.S. Food and Drug Administration (FDA) approval for its new drug Lifyorli (relacorilant). The treatment is characterized as a first-of-its-kind therapy specifically for platinum-resistant epithelial ovarian cancer when used in combination with nab-paclitaxel. Following the announcement, Corcept (CORT) shares jumped in the market as investors reacted positively to the regulatory milestone. Lifyorli works as a selective glucocorticoid receptor antagonist, designed to modulate the effects of cortisol in patients. This approval marks a significant breakthrough for the company, offering a new therapeutic option for a particularly difficult-to-treat form of cancer. Analysts expect the commercial launch to drive substantial revenue growth for the biotechnology firm in the coming periods.